Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients

British Journal of Clinical Pharmacology

Volumn 55, Issue 3, 2003, Pages 270-277

  Lee, How Sung ^a,c   Goh, Boon Cher ^b   Fan, Lu ^a   Khoo, Yok Moi ^a   Wang, Lingzhi ^b   Lim, Robert ^b   Ong, Ai Bee ^b   Chua, Charlotte ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer and noncancer Asian patients; CYP3A; Midazolam

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; RACE DIFFERENCE;

ADOLESCENT; ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; ASIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDAZOLAM; MIDDLE AGED; NEOPLASMS; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE;

EID: 12244267678     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01767.x     Document Type: Article

References (33)

1. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Warkins PB. The human CYP3A subfamily: Practical considerations. Drug Metab Rev 2000; 32: 339-361.
2. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A; IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.
3. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guaelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989; 83: 688-697.
4. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89-96.
5. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolf T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidation drug metabolism. J Biol Chem 1986; 261: 5051-5060.
6. Marre F, Saderlink GJ, de Sousa G, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere®) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 1996; 56: 1296-1302.
7. Thummel KE, Wilkinson GR. In vitro and in vivo interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 1998; 38: 389-430.
8. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40: 523-530.
9. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000; 18: 2301-2308.
10. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-184.
11. Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethophan, and verapamil. Clin Pharmacol Ther 1999; 66: 40-50.
12. Streeman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187-216.
13. Kinirons MT, O'Shea D, Kim RB, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999; 66: 224-231.
14. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408-414.
15. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450, 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271: 549-556.
16. Backman JT, Olkkola KT, Neuvonen PJ. Rifampicin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59: 7-13.
17. Olkkola KT, Aranko K, Lunrila H, Hiller A, Saarnivaara L. A potential hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298-305.
18. Kupferschmidt HHT, Ha HR, Ziegler WH, Meire PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20-28.
19. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994; 271: 557-566.
20. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
21. Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by single-point determination of midazolam plasma concentration. Pharmacogenetics 2001; 11: 781-791.
22. Kim JS, Nafziger AN, Tsunoda SM, et al. Limited sampling strategy, to predict AUC of the CYP3A phenotyping probe midazolam in adults: Application to various assay techniques. J Clin Pharmacol 2002; 42: 376-382.
23. Tateishi T, Watanabe M, Nakura H, et al. CYP3A activity, in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 2001; 69: 333-339.
24. Balson KR, Morgan DJ, Richmond BH, McAlindon ME, Elliott SL, Yeomans ND. Sedation for endoscopy. Pharmacokinetics of midazolam in Vietnamese subjects. J Gastroenterol Hepatol 1996; 11: 1177-1180.
25. Muck W, Tanaka T, Ahr G, Kulmann J. No interethnic differences in steroselective disposition of oral nimodipine between Caucasian and Japanese subjects. Int J Clin Pharmacol Ther 1996; 34: 163-171.
26. Albrecht S, Ihmsen H, Hering W, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999; 65: 630-639.
27. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability, of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-3690.
28. Dundee JW, Halliday NJ, Harper KW, Brogden RN, Midazolam A review of its pharmacological properties and therapeutic use. Drugs 1984; 28: 519-543.
29. Bornemann LD, Min BH, Crews T, et al. Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol 1985; 29: 91-95.
30. Nakajima M, Suzuki T, Sasaki T, et al. Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. Ther Drug Monit 1999; 21: 507-513.
31. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983; 16: 43S-49S.
32. Hotz MA, Ritz R, Linder L, Scollo-Lavizzari G, Haefeli WE. Auditory and electroencephalographic effects of midazolam and á-hydroxy-midazolam in healthy subjects. Br J Clin Pharmacol 2000; 49: 72-79.
33. Zimmerman CL, Slattery JT. Maintenance-dose prediction based on a single determination of concentration: general applicability to two-compartment drugs with reference to lithium. J Pharm Sci 1983; 72: 1262-1266.